HOXA5 was also highly expressed in primary glioma (P <0.001, respectively; Figure 2E), whereas the analysis for first-course treatment outcome showed that progressive disease was correlated with higher expression of HOXA5 (P <0.001, respectively; Figure 2F). Here, HOXA5 is linked to central nervous system cancer.